Table 5.
List of significant public compounds in CMAP analysis
| Compound | P-value | Specificity | Therapy area | Pharmacological action | Indication | Target |
|---|---|---|---|---|---|---|
| Disopyramide | 0 | 0.0006 | Cardiovascular | Sodium channel blocker | Arrhythmia | SCN5A, ORM1 |
| Biperiden | 0.0005 | 0.0984 | Neurological | Muscarinic acetylcholine receptor antagonist | Parkinsonism | CHRNA2, CHRM1 |
| Remoxipride | 0.0036 | 0.0164 | Neurological | Dopamine receptor D2 antagonist | Schizophrenia | DRD2 |
| Suramin sodium | 0.0101 | 0.0129 | Anti-infective | Topoisomerase inhibitor | African trypanosomiasis | P2RY2, SIRT5, FSHR |
| Flunarizine | 0.0133 | 0.0119 | Cardiovascular | Voltage-gated calcium channel blocker; sodium channel antagonist | Migraine, epilepsy | HRH1, CACNA1G, CACNA1H, CACNA1I, CALM1 |
| Adenosine phosphate | 0.019 | 0.0007 | Cardiovascular | Calcium channel blocker | Arrhythmia | Unknown |
| Ranitidine | 0.0332 | 0.049 | Miscellaneous | Histamine receptor H2 antagonist | Peptic Ulcer | HRH2 |
| Chloropyramine | 0.0355 | 0.0523 | Miscellaneous | Histamine H1 receptor antagonist | Antiallergic agent | HRH1 |
| Acetohexamide | 0.0408 | 0.0508 | Cardiovascular | Blocking of ATP-sensitive K+ channel | Diabetes mellitus type 2 | KCNJ1 |
| Dobutamine | 0.0411 | 0.0665 | Cardiovascular | Adrenoreceptor agonist (beta1) | Cardiac decompensation | ADRB1 |
| Mephenytoin | 0.0441 | 0.0444 | Cardiovascular | Sodium channel inhibitor | Seizures | SCN5A, ALB |
| Testosterone | 0.0476 | 0.0783 | Miscellaneous | Androgen receptor agonist | Hypogonadism | AR, ALB, SHBG, NPPB |
| Dienestrol | 0.0483 | 0.0982 | Miscellaneous | Estrogen | Atrophic vaginitis | ESR1 |